A Phase 1b/2 investigator-sponsored trial to evaluate combination treatment of an approved PARP inhibitor and sapacitabine in patients with BRCA mutant breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Sapacitabine (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 04 Apr 2018 New trial record
- 28 Mar 2018 According to a Cyclacel Pharmaceuticals media release, enrollment will be initiated in 2018.
- 28 Mar 2018 According to a Cyclacel Pharmaceuticals media release, in collaboration with an academic center the company has developed a protocol for this trial.